Actinium Pharmaceuticals IncNYSE American:ATNM
- LAST PRICE9.0800
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots8.6300/ 3
- Ask / Lots9.7800/ 1
- Open / Previous Close0.0000 / 9.0800
- Day Range---
- 52 Week Range
- Volume610
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ATNM |
|---|---|---|
| 09:32 ET | 1637 | 9.31 |
| 09:34 ET | 300 | 9.22 |
| 09:38 ET | 100 | 9.25 |
| 09:39 ET | 100 | 9.22 |
| 09:45 ET | 300 | 9.22 |
| 09:50 ET | 11859 | 9.4 |
| 09:52 ET | 5237 | 9.445 |
| 10:06 ET | 100 | 9.44 |
| 10:10 ET | 900 | 9.355 |
| 10:14 ET | 400 | 9.41 |
| 10:21 ET | 11788 | 9.36 |
| 10:24 ET | 500 | 9.3613 |
| 10:26 ET | 415 | 9.36 |
| 10:33 ET | 175 | 9.355 |
| 10:37 ET | 1000 | 9.3549 |
| 10:39 ET | 1962 | 9.41 |
| 10:42 ET | 2162 | 9.4 |
| 10:44 ET | 200 | 9.425 |
| 10:46 ET | 367 | 9.43 |
| 10:50 ET | 200 | 9.39 |
| 10:51 ET | 900 | 9.35 |
| 10:53 ET | 100 | 9.3 |
| 11:00 ET | 100 | 9.295 |
| 11:06 ET | 985 | 9.25 |
| 11:11 ET | 400 | 9.225 |
| 11:13 ET | 1078 | 9.2319 |
| 11:24 ET | 200 | 9.31 |
| 11:33 ET | 1400 | 9.27 |
| 11:36 ET | 327 | 9.26 |
| 11:44 ET | 300 | 9.25 |
| 11:45 ET | 1000 | 9.24 |
| 11:49 ET | 200 | 9.23 |
| 11:51 ET | 200 | 9.22 |
| 11:54 ET | 4353 | 9.15 |
| 11:58 ET | 100 | 9.17 |
| 12:00 ET | 600 | 9.215 |
| 12:03 ET | 1100 | 9.23 |
| 12:05 ET | 100 | 9.26 |
| 12:07 ET | 4647 | 9.17 |
| 12:09 ET | 100 | 9.16 |
| 12:12 ET | 2000 | 9.1301 |
| 12:14 ET | 4965 | 9.11 |
| 12:16 ET | 2917 | 9.07 |
| 12:18 ET | 800 | 9.05 |
| 12:20 ET | 1200 | 9.07 |
| 12:23 ET | 100 | 9.07 |
| 12:27 ET | 1789 | 8.9868 |
| 12:30 ET | 300 | 8.98 |
| 12:32 ET | 100 | 8.985 |
| 12:34 ET | 2100 | 8.99 |
| 12:36 ET | 600 | 9.0101 |
| 12:38 ET | 200 | 9.07 |
| 12:41 ET | 100 | 9.13 |
| 12:48 ET | 2830 | 9.08 |
| 12:54 ET | 100 | 9.08 |
| 12:57 ET | 200 | 9.1 |
| 12:59 ET | 913 | 9.08 |
| 01:03 ET | 600 | 9.0352 |
| 01:10 ET | 551 | 9.065 |
| 01:12 ET | 100 | 9.065 |
| 01:14 ET | 100 | 9.07 |
| 01:15 ET | 100 | 9.0493 |
| 01:17 ET | 200 | 9.075 |
| 01:19 ET | 100 | 9.05 |
| 01:26 ET | 100 | 9.04 |
| 01:37 ET | 100 | 9.07 |
| 01:39 ET | 2600 | 9.064 |
| 01:42 ET | 450 | 9.05 |
| 01:44 ET | 500 | 9.09 |
| 01:50 ET | 500 | 9.07 |
| 01:51 ET | 400 | 9.09 |
| 02:02 ET | 100 | 9.105 |
| 02:04 ET | 200 | 9.105 |
| 02:06 ET | 100 | 9.105 |
| 02:08 ET | 100 | 9.06 |
| 02:09 ET | 300 | 9.09 |
| 02:18 ET | 434 | 9.13 |
| 02:20 ET | 100 | 9.15 |
| 02:27 ET | 1086 | 9.13 |
| 02:31 ET | 400 | 9.13 |
| 02:45 ET | 100 | 9.17 |
| 02:51 ET | 200 | 9.18 |
| 02:56 ET | 577 | 9.22 |
| 02:58 ET | 300 | 9.215 |
| 03:00 ET | 300 | 9.215 |
| 03:02 ET | 700 | 9.18 |
| 03:03 ET | 100 | 9.16 |
| 03:07 ET | 1500 | 9.11 |
| 03:09 ET | 300 | 9.13 |
| 03:12 ET | 400 | 9.13 |
| 03:16 ET | 100 | 9.135 |
| 03:20 ET | 500 | 9.14 |
| 03:21 ET | 500 | 9.1 |
| 03:23 ET | 650 | 9.105 |
| 03:27 ET | 200 | 9.0765 |
| 03:32 ET | 600 | 9.1 |
| 03:34 ET | 100 | 9.115 |
| 03:36 ET | 997 | 9.14 |
| 03:41 ET | 374 | 9.135 |
| 03:43 ET | 1050 | 9.12 |
| 03:45 ET | 375 | 9.14 |
| 03:48 ET | 100 | 9.12 |
| 03:50 ET | 600 | 9.13 |
| 03:52 ET | 100 | 9.145 |
| 03:56 ET | 662 | 9.13 |
| 03:57 ET | 100 | 9.135 |
| 03:59 ET | 1626 | 9.08 |
Mar 16, 2023
Actinium to Showcase First-In-Class Targeted Radiotherapies in Two Presentations at the 2023 AACR Annual Meeting, from 8:45AM ET on Thursday Mar 16, 2023 by PR Newswire
8:45AM ET on Thursday Mar 16, 2023 by PR Newswire
Mar 15, 2023
Actinium Pharmaceuticals, Inc. to Present at Oppenheimer's 33rd Annual Healthcare Conference, from 8:00AM ET on Wednesday Mar 15, 2023 by PR Newswire
8:00AM ET on Wednesday Mar 15, 2023 by PR Newswire
Mar 10, 2023
BRIEF-Actinium Pharmaceuticals Inc - Does Not Hold Any Deposits Or Securities Or Maintain Any Accounts At Silicon Valley Bank, from 5:45PM ET on Friday Mar 10, 2023 by Thomson Reuters
5:45PM ET on Friday Mar 10, 2023 by Thomson Reuters
Mar 2, 2023
B. Riley Raises Actinium Pharmaceuticals' Price Target to $20 From $18, Keeps Buy Rating, from 8:08AM ET on Thursday Mar 02, 2023 by MT Newswires
8:08AM ET on Thursday Mar 02, 2023 by MT Newswires
Feb 27, 2023
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Actinium Pharmaceuticals Inc | 231.4M | -7.0x | --- |
Savara Inc | 231.5M | -7.6x | --- |
PMV Pharmaceuticals Inc | 231.2M | -3.1x | --- |
Oculis Holding AG | 228.8M | 162.0x | --- |
Celcuity Inc | 234.2M | -4.1x | --- |
ATAI Life Sciences NV | 227.4M | -1.4x | --- |
Company Information
Actinium Pharmaceuticals, Inc. is a clinical-stage, biopharmaceutical company. The Company is focused on developing and commercializing targeted radiotherapies to deliver cancer-killing radiation with cellular level precision to treat patients with high unmet needs. Its clinical programs use its Antibody Warhead Enabling (AWE) technology platform. Its clinical pipeline is led by Antibody Radiation-Conjugates (ARCs). Its lead product candidate, Iomab-B (I-131 apamistamab), is a targeted conditioning agent, which consists of an anti-CD45 monoclonal antibody and the radioisotope Iodine-131 (I-131). Its clinical and preclinical development programs utilize multiple isotopes, including Actinium-225, Iodine-131 and Lutetium-177 directed at multiple validated cancer targets, including CD45, CD33, CD38, CD47, HER2 and HER3 for targeted conditioning prior to cell and gene therapies, including bone marrow transplant (BMT) and cancer therapeutics in combination with other therapeutic modalities.
Contact Information
- Headquarters
- 275 Madison Avenue, 7Th FloorNEW YORK, NY, United States 10016
- Phone
- 646-677-3875
- Fax
- 845-818-3588
Executives
- Chairman of the Board, Chief Executive Officer
- Sandesh Seth
- Chief Financial Officer, Corporate Secretary
- Steve O'Loughlin
- Independent Director
- Jeffrey Chell
- Lead Independent Director
- C. David Nicholson
- Independent Director
- Ajit Shetty
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $231.4M |
|---|---|
Revenue (TTM) | $1.1M |
Shares Outstanding | 25.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.40 |
EPS | $-1.30 |
Book Value | $3.32 |
P/E Ratio | -7.0x |
Price/Sales (TTM) | 219.7 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -2,930.77% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
